One study showed that R-Spondin 2 inhibits PI3K/AKT/eNOS signaling by R-Spondin 2 receptor LGR4 and inhibits lymphangiogenesis, which may provide evidence for new therapeutic strategies to promote lymphangiogenesis and improve cholesterol efflux from atherosclerosis (Singla et al., 2020). The gene discussed is PIK3CD; the disease is atherosclerosis.